RSLV-132

Home
Ligands
RSLV-132

GtoPdb Ligand ID: 10412

Synonyms: RSLV132

Comment: RSLV-132 is a fully human biologic fusion protein that is comprised of human RNase fused to the Fc domain of human IgG1 [1]. The peptide sequence of RSLV-132 has not yet been formally disclosed. It is designed to digest circulating extracellular RNA autoantigens that are known to trigger inflammatory responses in some chronic autoinflammatory conditions. RSLV-132 is proposed for anti-inflammatory and immunomodulatory activities in such conditions. It may also be effective in reducing viral RNA load and/or persistence in virus reservoirs.

References
1. Burge DJ, Eisenman J, Byrnes-Blake K, Smolak P, Lau K, Cohen SB, Kivitz AJ, Levin R, Martin RW, Sherrer Y et al.. (2017) Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study. Lupus, 26 (8): 825-834. [PMID:27852935]
2. Burge DJ, Werth VP, Boackle SA, Posada J. (2024) Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132. Lupus Sci Med, 11 (1). [PMID:38325898]
3. Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. (2021) Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev, 3 (3): CD007478. [PMID:33687069]
4. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature, 416 (6881): 603-7. [PMID:11948342]
5. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. (2004) Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum, 50 (6): 1861-72. [PMID:15188363]
6. Posada J, Valadkhan S, Burge D, Davies K, Tarn J, Casement J, Jobling K, Gallagher P, Wilson D, Barone F et al.. (2021) Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial. Arthritis Rheumatol, 73 (1): 143-150. [PMID:32798283]

References

1. Burge DJ, Eisenman J, Byrnes-Blake K, Smolak P, Lau K, Cohen SB, Kivitz AJ, Levin R, Martin RW, Sherrer Y et al.. (2017)
Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study.
Lupus, 26 (8): 825-834. [PMID:27852935]

2. Burge DJ, Werth VP, Boackle SA, Posada J. (2024)
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Lupus Sci Med, 11 (1). [PMID:38325898]

3. Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. (2021)
Interventions for cutaneous disease in systemic lupus erythematosus.
Cochrane Database Syst Rev, 3 (3): CD007478. [PMID:33687069]

4. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. (2002)
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.
Nature, 416 (6881): 603-7. [PMID:11948342]

5. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. (2004)
Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG.
Arthritis Rheum, 50 (6): 1861-72. [PMID:15188363]

6. Posada J, Valadkhan S, Burge D, Davies K, Tarn J, Casement J, Jobling K, Gallagher P, Wilson D, Barone F et al.. (2021)
Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
Arthritis Rheumatol, 73 (1): 143-150. [PMID:32798283]